Bulevirtide

• Description :

  Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research[1][2].

• Product Name Alternative :

  Myrcludex B

• UNSPSC :

  12352209

• Target :

  HBV

• Type :

  Peptides

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/bulevirtide.html

• Purity :

  99.70

• Solubility :

  DMSO : 50 mg/mL (ultrasonic) |H2O : 83.33 mg/mL (ultrasonic; adjust pH to 8 with NH3·H2O)

• Smiles :

  O=C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](C(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CC(N)=O)C(N2[C@@H](CCC2)C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=CC=C4)C(N5[C@@H](CCC5)C(N[C@@H](CC(O)=O)C(N[C@@H](CC6=CNC=N6)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N7[C@@H](CCC7)C(N[C@@H](C)C(N[C@@H](CC8=CC=CC=C8)C(NCC(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(N)=O)C(N9[C@@H](CCC9)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%10=CNC%11=CC=CC=C%10%11)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%12=CC=CC=C%12)C(N[C@@H](CC(N)=O)C(N%13[C@@H](CCC%13)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%14=CNC=N%14)C(N[C@@H](CC%15=CNC%16=CC=CC=C%15%16)C(N%17[C@@H](CCC%17)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(NCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CNC(CCCCCCCCCCCCC)=O

• Molecular Formula :

  C248H355N65O72

• Molecular Weight :

  5398.86

• References & Citations :

  [1]Masetti C, et al. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver Int. 2021 Jul;41 (7) :1441-1442.|[2]Cheng D, et al. Clinical effects of NTCP-inhibitor myrcludex B. J Viral Hepat. 2021 Jun;28 (6) :852-858.|[3]Donkers JM, et al., Mechanistic insights into the inhibition of NTCP by myrcludex B. JHEP Rep. 2019 Aug 1;1 (4) :278-285.|[4]Volz T, et al., The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013 May;58 (5) :861-7.|[5]Zhao K, et al., Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect. 2018 Nov 21;7 (1) :186.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

• Scientific Category :

  Peptides

• Clinical Information :

  Launched

• CAS Number :

  [2012558-47-1]